Long-Term Use of Rimegepant 75 mg for the Acute Treatment of Migraine is Associated with a Reduction in the Utilization of Select Analgesics and Antiemetics

References

• Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. doi:10.1177/0333102417738202
   PubMed Web of Science ®Google Scholar
• Chen PK, Wang SJ. Non-headache symptoms in migraine patients. F1000Res. 2018;7:188. doi:10.12688/f1000research.12447.1
   PubMedGoogle Scholar
• Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z; on behalf of Lifting The Burden: the Global Campaign against H. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137. doi:10.1186/s10194-020-01208-0
   PubMed Web of Science ®Google Scholar
• Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–1222. doi:10.1016/S0140-6736(20)30925-9
   PubMed Web of Science ®Google Scholar
• Katsuki M, Matsumori Y, Kawahara J, et al. Headache education by leaflet distribution during COVID-19 vaccination and school-based on-demand e-learning: itoigawa geopark headache awareness campaign. Headache. 2023;63(3):429–440. doi:10.1111/head.14472
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Birbeck GL, Jensen RH, et al. The Global Campaign turns 18: a brief review of its activities and achievements. J Headache Pain. 2022;23(1):49. doi:10.1186/s10194-022-01420-0
   PubMed Web of Science ®Google Scholar
• Cooper W, Doty EG, Hochstetler H, Hake A, Martin V. The current state of acute treatment for migraine in adults in the United States. Postgrad Med. 2020;132(7):581–589. doi:10.1080/00325481.2020.1767402
   PubMed Web of Science ®Google Scholar
• Ailani J, Burch RC, Robbins MS; on behalf of the Board of Directors of the American Headache Society. The American headache society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021–1039. doi:10.1111/head.14153
   PubMed Web of Science ®Google Scholar
• Pfizer Inc [Internet]. Nurtec® ODT (rimegepant) orally disintegrating tablets [prescribing information]; 2020. Available from: https://labeling.pfizer.com/ShowLabeling.aspx?id=19036. Accessed May 3, 2024.
   Google Scholar
• Pfizer Limited [Internet]. Vydura® (rimegepant) 75mg oral lyophilisate [prescribing information]; 2022. Available from: https://www.pfizerpro.co.uk/medicine/vydura. Accessed May 3, 2024.
   Google Scholar
• Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, Phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737–745. doi:10.1016/S0140-6736(19)31606-X
   PubMed Web of Science ®Google Scholar
• Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381(2):142–149. doi:10.1056/NEJMoa1811090
   PubMed Web of Science ®Google Scholar
• Yu S, Kim BK, Guo A, et al. Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2023;22(6):476–484. doi:10.1016/S1474-4422(23)00126-6
   PubMed Web of Science ®Google Scholar
• Croop R, Berman G, Kudrow D, et al. A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine. Cephalalgia. 2024;44(4):03331024241232944.
   Google Scholar
• Xu X, Ji Q, Shen M. Patient preferences and values in decision making for migraines: a systematic literature review. Pain Res Manag. 2021;2021:9919773. doi:10.1155/2021/9919773
   PubMed Web of Science ®Google Scholar
• Trigo-López J, Guerrero-Peral ÁL, Sierra Á, et al. Patients and general practitioners assessment of the main outcomes employed in the acute and preventive treatment of migraine: a cross sectional study. BMC Neurol. 2021;21(1):279. doi:10.1186/s12883-021-02220-w
   PubMed Web of Science ®Google Scholar
• Gallagher R. What do patients want from acute migraine treatment? Cephalalgia. 2004;24(Suppl 2):8–15. doi:10.1111/j.1468-2982.2004.00893.x
   PubMed Web of Science ®Google Scholar
• Smelt AFH, Louter MA, Kies DA, et al. What do patients consider to be the most important outcomes for effectiveness studies on migraine treatment? Results of a Delphi Study. PLoS One. 2014;9(6):e98933. doi:10.1371/journal.pone.0098933
   PubMed Web of Science ®Google Scholar
• Diener H-C, Holle-Lee D, Nägel S, et al. Treatment of migraine attacks and prevention of migraine: guidelines by the German migraine and headache society and the German society of neurology. Clin Transl Neurol. 2019;3(1):2514183X18823377. doi:10.1177/2514183X18823377
   Google Scholar
• Hird MA, Sandoe CH. Medication overuse headache: an updated review and clinical recommendations on management. Curr Neurol Neurosci Rep. 2023;23(7):389–398. doi:10.1007/s11910-023-01278-y
   PubMed Web of Science ®Google Scholar
• Tai FWD, McAlindon ME. Non-steroidal anti-inflammatory drugs and the gastrointestinal tract. Clin Med. 2021;21(2):131–134. doi:10.7861/clinmed.2021-0039
   PubMed Web of Science ®Google Scholar
• Varga Z, Sabzwari SRA, Vargova V. Cardiovascular risk of nonsteroidal anti-inflammatory drugs: an under-recognized public health issue. Cureus. 2017;9(4):e1144. doi:10.7759/cureus.1144
   PubMed Web of Science ®Google Scholar
• Luo G, Huang L, Zhang Z. The molecular mechanisms of Acetaminophen-induced hepatotoxicity and its potential therapeutic targets. Expl Biol Med. 2023;248(5):412–424. doi:10.1177/15353702221147563
   Web of Science ®Google Scholar
• Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of Acetaminophen daily: a randomized controlled trial. JAMA. 2006;296(1):87–93. doi:10.1001/jama.296.1.87
   PubMed Web of Science ®Google Scholar
• Nelson DA, Marks ES, Deuster PA, O’Connor FG, Kurina LM. Association of nonsteroidal anti-inflammatory drug prescriptions with kidney disease among active young and middle-aged adults. JAMA Network Open. 2019;2(2):e187896–187908. doi:10.1001/jamanetworkopen.2018.7896
   PubMed Web of Science ®Google Scholar
• Flake ZA, Scalley RD, Bailey AG. Practical selection of antiemetics. Am Fam Physician. 2004;69(5):1169–1174.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Munjal S, Buse DC, Fanning KM, Bennett A, Reed ML. Predicting inadequate response to acute migraine medication: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2016;56(10):1635–1648. doi:10.1111/head.12941
   PubMed Web of Science ®Google Scholar